Sign In
Buy PCRX
$26.41
-0.560 (-2.08%)
At Close: Jul 31, 2026
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
08:00am, Monday, 27'th Jul 2026
— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product from new manufacturing process — — Topline data from Part A of Phase 2 ASCEND study remains on
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $29.40
01:59am, Sunday, 26'th Jul 2026
Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX - Get Free Report) have been assigned an average recommendation of "Hold" from the seven brokerages that are covering the stock, Marketbeat reports. On
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
08:00am, Wednesday, 22'nd Jul 2026
BRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Wednesday, 08'th Jul 2026
BRISBANE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of pati
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
10:30am, Wednesday, 01'st Jul 2026
PCRX is set to sell its iovera franchise to ZBH in a deal worth up to $140M as it sharpens focus on biopharmaceutical growth.
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
08:00am, Wednesday, 01'st Jul 2026
-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
07:30am, Tuesday, 30'th Jun 2026
-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments -- -- Two companies will collaborate on advanc
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
05:53pm, Tuesday, 09'th Jun 2026
BRISBANE, Calif., June 9, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain thera
Pacira BioSciences, Inc. (PCRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
03:28pm, Monday, 08'th Jun 2026
Pacira BioSciences, Inc. (PCRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Election of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward Momentum Leading Independent Experts ISS, Glass Lewis and Egan-Jones Agree that DOMA Representation Is Not Warran
ISS Concludes "There is a Compelling Reason to Support all Management Nominees" and Notes "the Dissident Has Not Presented a Compelling Case for Change" BRISBANE, Calif., June 1, 2026 /PRNewswire/ --
PharmaCorp Rx Inc. Announces First Quarter 2026 Financial Results
09:00am, Monday, 01'st Jun 2026
First quarter 2026 revenue up 79.4% compared to the first quarter of 2025 First quarter 2026 gross profit increased 71.9% compared to the first quarter of 2025 First quarter same-store sales were up 7
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira's Director Nominees
04:20pm, Thursday, 28'th May 2026
BRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid
PACIRA'S STOCK PRICE IS DOWN FOR EVERY RECENT PERIOD: 10 YEAR, 5 YEAR, 3 YEAR, 2 YEAR, ONE YEAR, AND YEAR-TO-DATE DOMA BELIEVES MANAGEMENT IS MISLEADING STAKEHOLDERS REGARDING ITS PATENT PROTECTION AN
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified Nominees
04:20pm, Wednesday, 27'th May 2026
Clarifies DOMA's Inaccuracies and the Reality of Pacira' Efforts to Strengthen its Market Position Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BL
